rosiglitazone has been researched along with Death, Sudden, Cardiac in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Aquilante, CL; Bilker, WB; Bloomgarden, ZT; Brensinger, CM; Dawwas, GK; Deo, R; Dhopeshwarkar, N; Flory, JH; Gagne, JJ; Hennessy, S; Kimmel, SE; Leonard, CE; Soprano, SE | 1 |
| Mitka, M | 1 |
| Greyson, CR; Lu, L; Reiter, MJ; Sarraf, M; Schwartz, GG; Ye, S | 1 |
3 other study(ies) available for rosiglitazone and Death, Sudden, Cardiac
| Article | Year |
|---|---|
The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety.
Topics: Adult; Aged; Arrhythmias, Cardiac; Databases, Factual; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Male; Medicaid; Middle Aged; Pioglitazone; Protective Factors; Risk Assessment; Risk Factors; Rosiglitazone; Time Factors; Treatment Outcome; United States | 2020 |
FDA eases restrictions on the glucose-lowering drug rosiglitazone.
Topics: Death, Sudden, Cardiac; Diabetes Mellitus; Humans; Hypoglycemic Agents; Myocardial Infarction; Practice Patterns, Physicians'; Risk; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2013 |
Thiazolidinedione drugs promote onset, alter characteristics, and increase mortality of ischemic ventricular fibrillation in pigs.
Topics: Animals; Anti-Arrhythmia Agents; Coronary Vessels; Death, Sudden, Cardiac; Decanoic Acids; Female; Glyburide; Hydroxy Acids; Hypoglycemic Agents; Ischemia; Ischemic Preconditioning, Myocardial; Male; Pioglitazone; Potassium Channel Blockers; Rosiglitazone; Swine; Thiazolidinediones; Ventricular Fibrillation | 2012 |